The U.S. Department of Defense (DoD) is conducting market research on potential sources for development of an autoinjector drug-delivery device, or an already FDA-approved drug delivery device that will deliver therapies useful against nerve agent poisoning. The particular therapies of interest are the nerve agent antidotes atropine and pralidoxime chloride, as well as the anticonvulsants midazolam and diazepam.
System requirements include individual drug delivery platforms containing diazepam, midazolam, atropine, or pralidoxime chloride in the doses currently procured by the DoD. The dual delivery of the drug components atropine plus 2-pralidoxime in an autoinjector is the subject of a separate RFI, Solicitation Number: W911QY-14-S-CDP1.
The Service Member-carried device must be administrable by personnel in Mission Oriented Protective Posture 4 (MOPP-4) over-garments and mask, to a casualty in MOPP-4. The delivery device platform(s) and drug must be stable at operationally relevant temperatures to include temperature extremes experienced by Service Members in the field.
The effort is overseen by the Medical Countermeasure Systems-Chemical Defense Pharmaceuticals (MCS-CDP) Joint Product Management Office, which is responsible for the development, procurement, fielding, and sustaining of medical treatment and prophylactic capabilities against chemical, radiological and nuclear threats.
Further details are available under Solicitation Number: W911QY141CDP2.
